Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects

Dawei Xuan; Scott McBride; Philip Wastall; Anthony Porcari; Lorenzo DiCarlo; Rebecca A. Boyd

doi:10.1002/cpdd.232

Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects

Clinical Pharmacology in Drug Development ◽

10.1002/cpdd.232 ◽

2015 ◽

Vol 5 (1) ◽

pp. 13-26 ◽

Cited By ~ 2

Author(s):

Dawei Xuan ◽

Scott McBride ◽

Philip Wastall ◽

Anthony Porcari ◽

Lorenzo DiCarlo ◽

...

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cpp45335 ◽

2007 ◽

Vol 45 (06) ◽

pp. 335-344 ◽

Cited By ~ 111

Author(s):

W. Mueck ◽

M. Becka ◽

D. Kubitza ◽

B. Voith ◽

M. Zuehlsdorf

Keyword(s):

Population Model ◽

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

The Journal of Clinical Pharmacology ◽

10.1002/jcph.5 ◽

2013 ◽

Vol 53 (3) ◽

pp. 249-255 ◽

Cited By ~ 59

Author(s):

Dagmar Kubitza ◽

Michael Becka ◽

Angelika Roth ◽

Wolfgang Mueck

Keyword(s):

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics ◽

Age And Gender ◽

And Gender

Download Full-text

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

Clinical Pharmacokinetics ◽

10.2165/00003088-200847030-00006 ◽

2008 ◽

Vol 47 (3) ◽

pp. 203-216 ◽

Cited By ~ 175

Author(s):

Wolfgang Mueck ◽

Bengt I Eriksson ◽

Kenneth A Bauer ◽

Lars Borris ◽

Ola E Dahl ◽

...

Keyword(s):

Population Pharmacokinetics ◽

Orthopaedic Surgery ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics ◽

Population Pharmacokinetics And Pharmacodynamics ◽

Major Orthopaedic Surgery

Download Full-text

Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects

The Journal of Clinical Pharmacology ◽

10.1177/0091270005281818 ◽

2006 ◽

Vol 46 (1) ◽

pp. 45-51 ◽

Cited By ~ 7

Author(s):

Anne Paccaly ◽

Annke Frick ◽

Marie-Laure Ozoux ◽

Valeria Chu ◽

Ronald Rosenburg ◽

...

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor

Download Full-text

Effect of Food, an Antacid, and the H2Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

The Journal of Clinical Pharmacology ◽

10.1177/0091270006286904 ◽

2006 ◽

Vol 46 (5) ◽

pp. 549-558 ◽

Cited By ~ 171

Author(s):

Dagmar Kubitza ◽

Michael Becka ◽

Michael Zuehlsdorf ◽

Wolfgang Mueck

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Effect Of Food

Download Full-text

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Journal of Cardiovascular Pharmacology ◽

10.1097/fjc.0b013e3182970991 ◽

2013 ◽

Vol 62 (2) ◽

pp. 212-221 ◽

Cited By ~ 35

Author(s):

Jeanne Mendell ◽

Frank Lee ◽

Shuquan Chen ◽

Valerie Worland ◽

Minggao Shi ◽

...

Keyword(s):

Factor Xa ◽

Antiplatelet Agents ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

British Journal of Clinical Pharmacology ◽

10.1111/bcp.12054 ◽

2013 ◽

Vol 76 (1) ◽

pp. 89-98 ◽

Cited By ~ 91

Author(s):

Dagmar Kubitza ◽

Angelika Roth ◽

Michael Becka ◽

Abir Alatrach ◽

Atef Halabi ◽

...

Keyword(s):

Single Dose ◽

Hepatic Impairment ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects

Journal of International Medical Research ◽

10.1177/030006051204000508 ◽

2012 ◽

Vol 40 (5) ◽

pp. 1688-1707 ◽

Cited By ~ 24

Author(s):

D Kubitza ◽

M Becka ◽

A Roth ◽

W Mueck

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor

Download Full-text

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

British Journal of Clinical Pharmacology ◽

10.1111/j.1365-2125.2009.03390.x ◽

2009 ◽

Vol 68 (1) ◽

pp. 77-88 ◽

Cited By ~ 37

Author(s):

Xia Zhao ◽

Peihong Sun ◽

Ying Zhou ◽

Yuwang Liu ◽

Huilin Zhang ◽

...

Keyword(s):

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics ◽

Multiple Doses ◽

Healthy Chinese ◽

Chinese Subjects

Download Full-text

PHARMACODYNAMIC INTERACTION BETWEEN TAK-442, AN ORAL DIRECT FACTOR XA INHIBITOR, AND PRASUGREL IN HEALTHY SUBJECTS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(11)61504-0 ◽

2011 ◽

Vol 57 (14) ◽

pp. E1504

Author(s):

Nolan Wood ◽

Fran Stringer ◽

Ruishan Wu ◽

Masaki Kawamura ◽

Jeff Spaeder

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacodynamic Interaction

Download Full-text

Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban  an oral, direct Factor Xa inhibitor  in healthy subjects

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects

Effect of Food, an Antacid, and the H2Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

PHARMACODYNAMIC INTERACTION BETWEEN TAK-442, AN ORAL DIRECT FACTOR XA INHIBITOR, AND PRASUGREL IN HEALTHY SUBJECTS

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects